Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
  • C07K14/08—RNA viruses
  • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
  • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2740/00—Reverse transcribing RNA viruses
  • C12N2740/00011—Details
  • C12N2740/10011—Retroviridae
  • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
  • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
  • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2740/00—Reverse transcribing RNA viruses
  • C12N2740/00011—Details
  • C12N2740/10011—Retroviridae
  • C12N2740/16011—Human Immunodeficiency Virus, HIV
  • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
  • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

• a polynucleotide comprising a nucleotide sequence encoding Vif wherein each of the amino acids corresponding to positions 127, 128, 130, 131, 132 and 142 of the sequence in Figure IA are replaced with another amino acid and wherein one or more of the amino acids corresponding to positions 22, 29, 41, 48, 66, 80, 109, 185 and 186 are not I 3 1, K, N 5 V 5 N, R 5 R and N respectively.
• amino acids corresponding to positions 127, 128, 130, 131, 132 and 142 are replaced with N, V, R, L, S and I respectively.
• amino acids corresponding to positions 22, 29, 41 48, 66, 80 and 109 are not I, I 5 K, N 5 V, N and R respectively.
• amino acids corresponding to positions 66, 80, 109, 127, 128, 130, 131, 132, 142, 185 and 186 are replaced with V, N, R, N, V, R, L, S, I, R and N respectively.
• amino acid corresponding to position 48 is N.
• amino acids corresponding to positions 29, 41, 48, 66, 80, 109, 127, 128, 13O 5 131, 132, 142, 185 and 186 are replaced with I, K, N, V, N, R, N 5 V, R, L, S 5 I, R and N respectively.
• the amino acid corresponding to position 22 is that present in a naturally occurring Vif, such as, but not limited to, HXB2 ace. #K03455, BRU accJ K02013, SF2 accJ K02007, PV22 acc.# K02083, MN acc.#M17449 and NL4-3 ace. # M19921 (see Figures IA, IB and 1C).
• a Suitable amino acid for this position is, but not limited to, K (Lysine).
• the fragment encoded by the polynucleotide further comprises a replacement amino acid at the amino acid corresponding to position 185 of the wild- type sequence in Figure IA.
• amino acid at position 109 of the wild-type sequence in Figure IA is altered to R.
• the vector of the present invention further comprises a polynucleotide sequence encoding a selection marker gene.
• the vector of the present invention further comprises a polynucleotide sequence encoding at least part of the low affinity nerve growth factor receptor (LNGFR).
• LNGFR low affinity nerve growth factor receptor
• the cell is a hematopoietic CD34+ precursor cell or a hematopoietic cell.
• the pharmaceutical composition of the present invention may be formulated to be delivered using a mini-pump or by a mucosal route, for example, as a nasal spray or aerosol for inhalation or ingestable solution, or parenterally in which the composition is formulated by an injectable form, for delivery, by, for example, an intravenous, intramuscular or subcutaneous route.
• the formulation may be designed to be delivered by both routes.
• Vif is one of the less immunogenic among the HIV-I proteins (Addo et al., 2003).
• the mutant Vif polypeptides of the present invention are not expected to differ significantly from WT- Vif under this respect, at least on the basis of both BIMAS (http://bimas.cit.nih.gov/) and RANKPEP (http://www. mifoundation.org/Tools/rankpep.html) algorithms for predicting HLA-I binding peptides (data not shown).
• Low immunogenicity and Tat-dependent expression of mutant Vif should avoid or at least minimize an immune response against uninfected retroviral-transduced cells in vivo.
• the wild-type HIV-I LTR guarantees very high expression levels of the transgene in HIV-I infected cells, a crucial requirement for the activity of a trans-dominant mutant protein.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Virology (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Immunology (AREA)
• Gastroenterology & Hepatology (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• AIDS & HIV (AREA)
• Tropical Medicine & Parasitology (AREA)
• Epidemiology (AREA)
• Hematology (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)

Priority Applications (9)

Applications Claiming Priority (4)

Publications (2)

Family

ID=37115522

Family Applications (1)

Country Status (9)

Cited By (1)

Families Citing this family (2)

Family Cites Families (2)

• 2006
  • 2006-03-07 KR KR1020077022937A patent/KR101411272B1/ko not_active Expired - Fee Related
  • 2006-03-07 AU AU2006238617A patent/AU2006238617B2/en not_active Ceased
  • 2006-03-07 CA CA2599525A patent/CA2599525C/en not_active Expired - Fee Related
  • 2006-03-07 ES ES06765488T patent/ES2377829T3/es active Active
  • 2006-03-07 AT AT06765488T patent/ATE533777T1/de active
  • 2006-03-07 US US11/815,490 patent/US8912152B2/en not_active Expired - Fee Related
  • 2006-03-07 EP EP06765488A patent/EP1883649B1/en not_active Not-in-force
  • 2006-03-07 WO PCT/IB2006/001519 patent/WO2006111866A2/en not_active Ceased
  • 2006-03-07 JP JP2008500292A patent/JP5324912B2/ja not_active Expired - Fee Related

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events